BIVV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIVV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bioverativ's average Accounts Payable for the three months ended in Dec. 2017 was $25 Mil. Bioverativ's Cost of Goods Sold for the three months ended in Dec. 2017 was $70 Mil. Hence, Bioverativ's Days Payable for the three months ended in Dec. 2017 was 32.26.
The historical rank and industry rank for Bioverativ's Days Payable or its related term are showing as below:
Bioverativ's Days Payable increased from Dec. 2016 (15.07) to Dec. 2017 (32.26). It may suggest that Bioverativ delayed paying its suppliers.
The historical data trend for Bioverativ's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioverativ Annual Data | |||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | ||||||
Days Payable | - | 143.05 | 84.18 | 18.03 | 25.33 |
Bioverativ Quarterly Data | ||||||||||||
Dec13 | Dec14 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | |
Days Payable | Get a 7-Day Free Trial | 15.07 | 20.69 | 18.82 | 28.42 | 32.26 |
For the Biotechnology subindustry, Bioverativ's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Bioverativ's Days Payable distribution charts can be found below:
* The bar in red indicates where Bioverativ's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Bioverativ's Days Payable for the fiscal year that ended in Dec. 2017 is calculated as
Days Payable (A: Dec. 2017 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (A: Dec. 2016 ) | + | Accounts Payable (A: Dec. 2017 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2017 ) | * | Days in Period |
= | ( (12.7 | + | 26.1) | / | 2 ) | / | 279.6 | * | 365 |
= | 19.4 | / | 279.6 | * | 365 | ||||
= | 25.33 |
Bioverativ's Days Payable for the quarter that ended in Dec. 2017 is calculated as:
Days Payable (Q: Dec. 2017 ) | |||||||||
= | Average Accounts Payable | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Accounts Payable (Q: Sep. 2017 ) | + | Accounts Payable (Q: Dec. 2017 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2017 ) | * | Days in Period |
= | ( (23.6 | + | 26.1) | / | 2 ) | / | 70.3 | * | 365 / 4 |
= | 24.85 | / | 70.3 | * | 365 / 4 | ||||
= | 32.26 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Bioverativ's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.
Alexander J Denner | director | C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Brian S Posner | director | 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John Cox | director, officer: Chief Executive Officer | C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
John Greene | officer: EVP, CFO and Treasurer | 51 LIME STREET, LONDON X0 EC3M 7DQ |
Geno J Germano | director | 5 GIRALDA FARMS, MADISON NJ 07940 |
Louis J Paglia | director | C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506 |
Anna Protopapas | director | MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Diantha Duvall | officer: Chief Accounting Officer | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140 |
Vivaldi Coelho Rogerio | officer: EVP, Chief Global Therapeutics | 225 SECOND AVENUE, WALTHAM MA 02451 |
Harris Timothy J.r. | officer: EVP, R & D | C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451 |
Lucia Celona | officer: EVP, HR & Corp Commun. Officer | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Richard Brudnick | officer: EVP, Business Development | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Biogen Inc. | 10 percent owner | 225 BINNEY STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By yifan900 yifan900 • 05-29-2018
By Sydnee Gatewood Sydnee Gatewood • 05-24-2017
By Mark Yu Mark Yu • 06-29-2017
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.